156 related articles for article (PubMed ID: 7641216)
1. Functional properties of FC-2.15, a monoclonal antibody that mediates human complement cytotoxicity against breast cancer cells.
Ballaré C; Barrio M; Portela P; Mordoh J
Cancer Immunol Immunother; 1995 Jul; 41(1):15-22. PubMed ID: 7641216
[TBL] [Abstract][Full Text] [Related]
2. Differential lytic and agglutinating activity of the anti-Lewis(x) monoclonal antibody FC-2.15 on human polymorphonuclear neutrophils and MCF-7 breast tumor cells. In vitro and ex vivo studies.
Capurro M; Ballaré C; Bover L; Portela P; Mordoh J
Cancer Immunol Immunother; 1999; 48(2-3):100-8. PubMed ID: 10414463
[TBL] [Abstract][Full Text] [Related]
3. Reactivity of monoclonal antibody FC-2.15 against drug resistant breast cancer cells. Additive cytotoxicity of adriamycin and taxol with FC-2.15.
Ballaré C; Portela P; Schiaffi J; Yomha R; Mordoh J
Breast Cancer Res Treat; 1998 Jan; 47(2):163-70. PubMed ID: 9497104
[TBL] [Abstract][Full Text] [Related]
4. Enhanced cytotoxicity against colon carcinoma by combinations of noncompeting monoclonal antibodies to the 17-1A antigen.
Fogler WE; Klinger MR; Abraham KG; Gottlinger HG; Riethmuller G; Daddona PE
Cancer Res; 1988 Nov; 48(22):6303-8. PubMed ID: 2460221
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody FC-5.01, directed against CD63 antigen, is internalized into cytoplasmic vesicles in the IIB-BR-G human breast cancer cell line.
Barrio MM; Portela P; Mordoh J
Hybridoma; 1998 Dec; 17(6):517-25. PubMed ID: 9890707
[TBL] [Abstract][Full Text] [Related]
6. Description of a new monoclonal antibody, FC-2.15, reactive with human breast cancer and other human neoplasias.
Mordoh J; Leis S; Bravo AI; Podhajcer OL; Ballare C; Capurro M; Kairiyama C; Bover L
Int J Biol Markers; 1994; 9(3):125-34. PubMed ID: 7829891
[TBL] [Abstract][Full Text] [Related]
7. IgM monoclonal antibody JD118 recognizes an inducible antigen target for human-complement-mediated cytotoxicity against neoplastic B cells.
Czuczman MS; Garin-Chesa P; Lemoli RM; Scheinberg DA
Cancer Immunol Immunother; 1993 Jun; 36(6):387-96. PubMed ID: 8500111
[TBL] [Abstract][Full Text] [Related]
8. FC-2.15, a monoclonal antibody active against human breast cancer, specifically recognizes Lewis(x) hapten.
Capurro M; Bover L; Portela P; Livingston P; Mordoh J
Cancer Immunol Immunother; 1998 Feb; 45(6):334-9. PubMed ID: 9490204
[TBL] [Abstract][Full Text] [Related]
9. Initial trial of bispecific antibody-mediated immunotherapy of CD15-bearing tumors: cytotoxicity of human tumor cells using a bispecific antibody comprised of anti-CD15 (MoAb PM81) and anti-CD64/Fc gamma RI (MoAb 32).
Ball ED; Guyre PM; Mills L; Fisher J; Dinces NB; Fanger MW
J Hematother; 1992; 1(1):85-94. PubMed ID: 1365020
[TBL] [Abstract][Full Text] [Related]
10. High expression of the antigen recognized by the monoclonal antibody GB24 on human breast carcinomas: a preventive mechanism of malignant tumor cells against complement attack?
Hofman P; Hsi BL; Manie S; Fenichel P; Thyss A; Rossi B
Breast Cancer Res Treat; 1994; 32(2):213-9. PubMed ID: 7532466
[TBL] [Abstract][Full Text] [Related]
11. Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity.
Kinouchi T; Bander NH; Kotake T
J Urol; 1995 Jul; 154(1):288-92. PubMed ID: 7776448
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibody homodimers: enhanced antitumor activity in nude mice.
Wolff EA; Schreiber GJ; Cosand WL; Raff HV
Cancer Res; 1993 Jun; 53(11):2560-5. PubMed ID: 8495420
[TBL] [Abstract][Full Text] [Related]
13. Selective cytotoxicity of murine monoclonal antibody LAM2 against human small-cell carcinoma in the presence of human complement: possible use for in vitro elimination of tumor cells from bone marrow.
Stahel RA; Mabry M; Sabbath K; Speak JA; Bernal SD
Int J Cancer; 1985 May; 35(5):587-92. PubMed ID: 2987136
[TBL] [Abstract][Full Text] [Related]
14. In vitro and in vivo antitumor effects of murine monoclonal antibody NCC-ST-421 reacting with dimeric Le(a) (Le(a)/Le(a)) epitope.
Watanabe M; Ohishi T; Kuzuoka M; Nudelman ED; Stroud MR; Kubota T; Kodairo S; Abe O; Hirohashi S; Shimosato Y
Cancer Res; 1991 Apr; 51(8):2199-204. PubMed ID: 1706961
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of antibody-dependent mechanisms of tumor cell lysis by a targeted activator of complement.
Imai M; Ohta R; Varela JC; Song H; Tomlinson S
Cancer Res; 2007 Oct; 67(19):9535-41. PubMed ID: 17909064
[TBL] [Abstract][Full Text] [Related]
16. Antibody dependent cellular cytotoxicity and complement mediated cytotoxicity on leukemic cells mediated by anti K562 monoclonal antibodies.
Tatake RJ; Maniar HS; Chiplunkar SV; Somasundaram R; Amin MK; Saikia T; Gangal SG
J Clin Lab Immunol; 1990 Feb; 31(2):87-91. PubMed ID: 1966990
[TBL] [Abstract][Full Text] [Related]
17. Phagocytosis of breast cancer cells mediated by anti-MUC-1 monoclonal antibody, DF3, and its bispecific antibody.
Akewanlop C; Watanabe M; Singh B; Walker M; Kufe DW; Hayes DF
Cancer Res; 2001 May; 61(10):4061-5. PubMed ID: 11358826
[TBL] [Abstract][Full Text] [Related]
18. Variables affecting the killing of cultured human neuroblastoma cells with monoclonal antibody and complement.
Duerst RE; Ryan DH; Frantz CN
Cancer Res; 1986 Jul; 46(7):3420-5. PubMed ID: 3708574
[TBL] [Abstract][Full Text] [Related]
19. G-CSF-stimulated PMN in immunotherapy of breast cancer with a bispecific antibody to Fc gamma RI and to HER-2/neu (MDX-210).
Repp R; Valerius T; Wieland G; Becker W; Steininger H; Deo Y; Helm G; Gramatzki M; Van de Winkel JG; Lang N
J Hematother; 1995 Oct; 4(5):415-21. PubMed ID: 8581378
[TBL] [Abstract][Full Text] [Related]
20. Murine monoclonal IgG3 antibodies to human colorectal tumor-associated antigens: production and characterization of antibodies active in both antibody-dependent cellular cytotoxicity and complement-mediated cytolysis.
Woodhouse CS; Morgan AC
Cancer Res; 1989 May; 49(10):2766-72. PubMed ID: 2713860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
